Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts

John Mascarenhas,Alexander Pristupa,Mark Drummond,Vikas Gupta,Suliman Al-Fayoumi,Jack W Singer,Tanya Granston,Ronald Hoffman,James P Dean,Catriona Jamieson,Moshe Talpaz,Aaron T Gerds,Claire Harrison,Robert Daly,Jason Gotlib,Ruben A Mesa ,Jennifer Callahan ,Anita Szőke ,Brady L Stein ,Srđan Verstovšek

doi:10.1182/blood.v128.22.lba-5.lba-5

Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts

John Mascarenhas, Alexander Pristupa + Show 18 more

Open Access

https://doi.org/10.1182/blood.v128.22.lba-5.lba-5

Copy DOI

Journal: Blood	Publication Date: Dec 2, 2016
Citations: 30

Affiliation: Icahn School of Medicine at Mount Sinai, Beatson West of Scotland Cancer Centre, Princess Margaret Cancer Centre, University of Toronto, CTI BioPharma (United States), University of California, San Diego, Michigan Center for Translational Pathology, University of Michigan–Ann Arbor, Cleveland Clinic, Guy's and St Thomas' NHS Foundation Trust, Stanford University, Stanford Medicine, Mayo Clinic, University of Szeged, Northwestern University, The University of Texas MD Anderson Cancer Center

#Best Available Therapy #Pacritinib + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.